/
BioXcel Therapeutics, Inc. (Nasdaq: BTAI, the Company ) is a biopharmaceutical company built on artificial intelligence ( AI ) to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology.
The business is unprofitable at the operating level (-7859.97% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 71.7% YoY. Margins deteriorated 4892.4pp alongside, both lines moving the wrong way.
Negative free cash flow of -$58M. The business is consuming cash, not generating it. Operating margin contracted 4892.4pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$680K
▼ -71.7% YoY
Net Income (TTM)
-$75M
▼ -17.3% YoY
Op. Margin
-7438.97%
▼ -4892.4pp YoY
ROIC
-37.33%
▲ +14.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$57M
▲ +20.0% YoY
Op. Cash Flow (TTM)
-$57M
▲ +20.0% YoY
Net Debt
$83M
Cash & Equiv.
$17M
3Y CAGR: +19.6%
Continue Research